DOCSLIB.ORG

Magnesium Causes Nitric Oxide Independent Coronary Artery Vasodilation in Humans Heart: First Published As 10.1136/Hrt.86.2.212 on 1 August 2001

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Magnesium Causes Nitric Oxide Independent Coronary Artery Vasodilation in Humans Heart: First Published As 10.1136/Hrt.86.2.212 on 1 August 2001 212 Heart 2001;86:212–216 Magnesium causes nitric oxide independent coronary artery vasodilation in humans Heart: first published as 10.1136/hrt.86.2.212 on 1 August 2001. Downloaded from H Teragawa, M Kato, T Yamagata, H Matsuura, G Kajiyama Abstract Objective—To determine how magnesium aVects human coronary arteries and whether endothe- lium derived nitric oxide (EDNO) is involved in the coronary arterial response to magnesium. Design—Quantitative coronary angiography and Doppler flow velocity measurements were used to determine the eVects of the nitric oxide synthase inhibitor NG-monomethyl-L-arginine (L-NMMA) on magnesium induced dilation of the epicardial and resistance coronary arteries. Setting—Hiroshima University Hospital a tertiary cardiology centre. Patients—17 patients with angiographically normal coronary arteries. Interventions—Magnesium sulfate (MgSO4) (0.02 mmol/min and 0.2 mmol/min) was infused for two minutes into the left coronary ostium before and after intracoronary infusion of L-NMMA. Main outcome measures—Diameter of the proximal and distal segments of the epicardial cor- onary arteries and coronary blood flow. Results—At a dose of 0.02 mmol/min, MgSO4 did not aVect the coronary arteries. At a dose of 0.2 mmol/min, MgSO4 caused coronary artery dilation (mean (SEM) proximal diameter 3.00 (0.09) to 3.11 (0.09) mm; distal 1.64 (0.06) to 1.77 (0.07) mm) and increased coronary blood flow (79.3 (7.5) to 101.4 (9.9) ml/min, p < 0.001 v baseline for all). MgSO4 increased the changes in these parameters after the infusion of L-NMMA (p < 0.001 v baseline). Conclusions—Magnesium dilates both the epicardial and resistance coronary arteries in humans. Furthermore, the coronary arterial response to magnesium is dose dependent and inde- pendent of EDNO. (Heart 2001;86:212–216) Keywords: coronary artery; coronary blood flow; magnesium sulfate; nitric oxide Much interest has been focused on the relation women) undergoing coronary angiography for http://heart.bmj.com/ between magnesium and cardiovascular the evaluation of chest pain. Chest pain was disease.1–3 Furthermore, the benefits of magne- atypical for eVort angina in all of the patients. sium administration have been shown in a vari- All patients had angiographically normal epi- ety of cardiovascular diseases.4–7 In the setting of cardial coronary arteries, normal left ventricu- coronary artery disease, several studies have lar function (contrast ventriculographic ejec- shown the eYcacy of magnesium infusion in tion fraction > 50%) and a normal coronary patients with acute myocardial infarction,4 va- flow reserve. Patients with angiographically 5 8 sospastic angina, and unstable angina. While documented coronary spasm (> 50% luminal on September 26, 2021 by guest. Protected copyright. several mechanisms are probably responsible for narrowing) after intracoronary injection of the favourable eVects of magnesium, the coron- acetylcholine were excluded from the study. ary vasodilatory eVect seems to be the primary No patients had a history of prior myocardial mechanism responsible for the beneficial eVects infarction, heart failure, or other serious of magnesium.9–11 However, only a few studies diseases. Written informed consent was ob- have investigated human coronary responses to tained from all patients before the study. The magnesium infusion in vivo.12 13 protocol was approved by the human investiga- One potential mechanism responsible for tion ethics committee of Hiroshima University. magnesium induced coronary dilation involves activation of the endothelium derived nitric The First Department oxide (EDNO) pathway.14–17 However, it is STUDY DESIGN of Internal Medicine, The study design has been previously de- unclear whether EDNO is involved in the Hiroshima University scribed in detail.18 In brief, all drugs including human coronary responses to magnesium. School of Medicine, antianginal agents were discontinued 48 hours 1-2-3 Kasumi, Therefore, in the present study we investigated before catheterisation, except for the unre- Minamiku, Hiroshima, the coronary vascular responses to intracoronary stricted use of sublingual glyceryl trinitrate, Japan 734-8851 infusion of magnesium. In addition, we deter- H Teragawa which was withheld 1 hour before catheterisa- mined whether EDNO contributes to the MKato tion. A 6 French guide catheter was introduced coronary vascular response to magnesium by T Yamagata into the left main coronary artery. A using NG-monomethyl-L-arginine (L-NMMA), H Matsuura 0.0014 inch Doppler flow guide wire (FloWire, G Kajiyama a nitric oxide synthase inhibitor. Cardiometrics, Mountain View, USA) was Correspondence to: advanced through the guide catheter into the Dr Teragawa Methods proximal segment of the left anterior descend- teragawa@ STUDY POPULATION ing coronary artery. The wire tip was carefully mcai.med.hiroshima-u.ac.jp We studied 17 Japanese patients (mean age 62 positioned in a straight segment of the vessel to Accepted 23 January 2001 years, range 44–69 years; seven men, 10 obtain an adequate flow velocity signal. www.heartjnl.com Magnesium and coronary dilation 213 <th;2> Table 1 Systemic haemodynamic and coronary diameter and blood flow variables Coronary diameter (mm) Heart: first published as 10.1136/hrt.86.2.212 on 1 August 2001. Downloaded from HR MAP (mm Coronary blood flow (beats/min) Hg) Proximal segments Distal segments (ml/min) Baseline before L-NMMA 68 (2) 108 (4) 3.00 (0.09) 1.64 (0.06) 79.3 (7.5) Low MgSO4 69 (2) 105 (4) 3.03 (0.09) 1.67 (0.06) 82.8 (7.3) High MgSO4 68 (3) 105 (4) 3.11 (0.09)*† 1.77 (0.07)*† 101.4 (9.9)*† Baseline after L-NMMA 67 (2) 108 (4) 2.89 (0.09)** 1.58 (0.06)** 68.3 (6.1)** Low MgSO4 68 (2) 106 (4) 2.93 (0.08) 1.62 (0.06) 71.7 (7.4) High MgSO4 67 (3) 106 (3) 3.01 (0.09)*† 1.67 (0.06)*‡ 86.2 (8.3)*† Glyceryl trinitrate 75 (3)§ 98 (4)¶ 3.26 (0.09)§ 1.95 (0.06)§ 98.4 (12.0)†† Values are mean (SEM). Low MgSO4 was at a dose of 0.02 mmol/min; high MgSO4 wasatadoseof0.2mmol/min. HR, heart rate; L-NMMA, NG-monomethy-L-arginine; MAP, mean arterial pressure. *p<0.001vbaseline; †p < 0.01 v low MgSO4;‡p<0.05vlow MgSO4; **p < 0.05 v baseline before L-NMMA;††p < 0.05 v oth- ers except high MgSO4;§p<0.001vothers; ¶p < 0.01 v others. STUDY PROTOCOL measured without knowledge of the clinical After baseline control conditions were estab- characteristics of the patients. An end diastolic lished, magnesium sulfate (MgSO4) was in- frame was selected and analysed by a computer fused at rates of 0.02 and 0.2 mmol/min for 2 assisted coronary angiographic analysis system minutes. These doses were determined based (CAAS II/QUANTCOR, Siemens AG, Berlin on preliminary studies performed in six other and Munich, Germany). The average values of patients who had undergone cardiac catheteri- triplicate measurements of luminal diameter sation. On the basis of these preliminary stud- were used for analysis. ies, intracoronary infusion of MgSO4 at the doses used in the present study had no eVects on either systemic haemodynamic variables or ESTIMATION OF CORONARY BLOOD FLOW systemic serum electrolyte concentrations and Coronary blood flow was calculated as the did not cause conduction disturbance. In con- product of coronary blood flow velocity and trast, these doses caused significant increases in vessel diameter using the following formula: × × × 2 the serum ionised magnesium concentration in ð average peak velocity 0.125 diameter . the coronary sinus (mean baseline concentra- For calculating coronary blood flow, the inter- tion (SEM): 0.50 (0.02) mmol/l; 0.02 mmol/ nal diameter of the vessel at the location of the flow measurements (2–3 mm distal to the wire min: 0.65 (0.04) mmol/l, p < 0.01 v baseline; 0.2 mmol/min: 1.65 (0.15) mmol/min, tip) was measured using the method described above. p < 0.001 v baseline). After 5 minutes, L-NMMA was infused into the left coronary http://heart.bmj.com/ artery at a rate of 40 µmol/min for five minutes. BIOCHEMICAL PARAMETERS After control conditions had been reestab- Venous blood was drawn from a femoral sheath lished, MgSO4 (0.02 and 0.2 mmol/min) was before the first and second administration of again infused serially. Finally, an intracoronary magnesium to measure serum ionised magne- infusion of glyceryl trinitrate was given at a rate sium and calcium concentrations using a selec- of 200 µg/min for one minute. All drugs were tive ion electrode (NOVA 8; NOVA Biomedi- infused directly into the left coronary ostium cal, Waltham, USA). All measurements were through a catheter using an infusion pump performed in duplicate. on September 26, 2021 by guest. Protected copyright. (TE-311, Terumo, Tokyo, Japan) set at a rate of 1 ml/min. Coronary angiography was performed under DRUG PREPARATIONS control conditions and at the end of each drug MgSO4 (Toa Pharmaceutical Co, Tokyo, administration. The coronary blood flow veloc- Japan) was dissolved in an isotonic glucose ity was monitored continuously by a 12 MHz solution. L-NMMA (Sigma) and glyceryl pulsed Doppler velocimeter (FloMap, Cardio- trinitrate (Nihonkayaku, Tokyo, Japan) were metrics). Arterial pressure, heart rate, and dissolved immediately before use in physiologi- ECG were monitored continuously and re- cal saline. L-NMMA was sterilised in the corded by a multichannel recorder (Ni- department of pharmacy of Hiroshima Univer- honkoden Polygraph System, Nihonkoden, sity Hospital. Tokyo, Japan). We waited at least five minutes after each drug infusion to obtain stable values STATISTICAL ANALYSIS for blood flow velocity and coronary diameter. All data are expressed as the mean (SEM). Serial changes in haemodynamic variables, QUANTITATIVE CORONARY ANGIOGRAPHY epicardial coronary diameter, and coronary The trunk of the left anterior descending and blood flow in response to MgSO4 were left circumflex coronary artery were divided compared by one way analysis of variance into the proximal and distal segments of equal (ANOVA).
Load more

Recommended publications
  • THE ACCUMULATION and DISTRIBUTION of EVANS BLUE in the KIDNEY of RATS FED NORMAL OR LOW MAGNESIUM DIETS by George Williams Seign
    THE ACCUMULATION AND DISTRIBUTION OF EVANS BLUE IN THE KIDNEY OF RATS FED NORMAL OR LOW MAGNESIUM DIETS by George Williams Seignious, IV Thesis submitted to the Graduate Faculty of the Virginia Polytechnic Institute and State University in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE in ! Biochemistry and Nutrition APPROVED: G. E. Bunce, Chairman R. E. Webb ______ fl" ________ M;O. ......... ..;:;...; ___'"";:,....:; __.;..,. ___ _ _.. ''-.::;,,/ ___ , _______ ,_.._~_ M. H. Samli R. G. Saacke August, 1973 Blacksburg, Virginia . l\CKNOWLEDGMEN',rS The author of this thesis would like to e~press his deepest thanks and gra'titU;de to for his.continued help, advice, and . ·. .. : .. - understanding which made this thesis possible •. A special note of ·"· thanks is expressed.to whos_e invaluable help, advice arid suggestions aided greatly the author's efforts. The author would also like to thank for his. help and advice in the lab and all the other graduate students who made the author's stay at Virginia.Tech i{ very pleasant _one. Thanks is expressed to the author's wife, , for .her love, understanding, encouragement, and typing which· enabled the completion of this thesis. Also the author would like.to thank his parents for their lc;rving support and financial assistance. ii 'TABLE OF CONTENTS ACKNOWLEDGMENTS ii. TABLE OF CONTENTS . iii I,.IST OF TABLES iv LIST OF FIGURES Vi LIST OF SELECTED CHEMICAL STRUCTURES vii LIST OF·ABBREVIATIONS viii INTRODUCTION 1 LITERATURE REVIEW 5 EXPERIMENTAL PROCEDURES RESULTS 33 DISCUSSION 74 SUMMARY 82 REFERENCES 85 VITA 88 iii ~· ,,;.
    [Show full text]
  • Magnesium Production
    Magnesium Production Subpart T, Greenhouse Gas Reporting Program Under the Greenhouse Gas Reporting Program (GHGRP), owners or operators of facilities that contain magnesium production processes must report emissions from use of cover and carrier gases as well as for all other source categories located at the facility for which methods are defined in the rule. Owners and operators are required to collect emission data, calculate greenhouse gas (GHG) emissions and follow the specified procedures for quality assurance, missing data, recordkeeping, and reporting per the requirements of 40 CFR Part 98 Subpart T – Magnesium Production. How Is This Source Category Defined? The magnesium production source category is defined as consisting of any process where magnesium metal is produced through smelting (including electrolytic smelting), refining, or remelting operations (including primary production facilities that extract magnesium from its ore and secondary production facilities that recover magnesium from scrap), or any process where molten magnesium is used in alloying, casting, drawing, extruding, forming, or rolling operations. Who Must Report? Magnesium production facilities that emit more than 25,000 metric tons CO2e per year. What Greenhouse Gases Must Be Reported? Each facility must report total annual emissions for each of the following greenhouse gases used in magnesium production facilities: ● Sulfur hexafluoride (SF6) ● HFC-134a ● The fluorinated ketone FK 5-1-12 ● Carbon dioxide (CO2) ● Any other GHG as defined in 40 CFR part 98, subpart A (General Provisions) of the rule In addition, the facility must report greenhouse gas emissions for any other source categories for which calculation methods are provided in the rule, as applicable.
    [Show full text]
  • Burning Magnesium, a Sparkle in Acute Inflammation: Gleams from Experimental Models
    Journal Identification = MRH Article Identification = 0418 Date: April 6, 2017 Time: 1:32 pm Magnesium Research 2017; 30 (1): 8-15 REVIEW Burning magnesium, a sparkle in acute inflammation: gleams from experimental models Sara Castiglioni, Alessandra Cazzaniga, Laura Locatelli, Jeanette AM Maier Dipartimento di Scienze Biomediche e Cliniche L. Sacco, Università di Milano, Milano, I-20157, Italy Correspondence: Dipartimento di Scienze Biomediche e Cliniche Luigi Sacco, Università di Milano, Via GB Grassi, 74 Milano 20157, Italy <[email protected]> Abstract. Magnesium contributes to the regulation of inflammatory responses. Here, we focus on the role of magnesium in acute inflammation. Although present knowledge is incomplete to delineate an accurate scenario and a sche- dule of the events occurring under magnesium deficiency, it emerges that low magnesium status favors the induction of acute inflammation by sensitizing sen- tinel cells to the noxious agent, and then by participating to the orchestration of the vascular and cellular events that characterize the process. Key words: magnesium, acute inflammation, leukocytes, endothelial cells Inflammation has been observed since the pathological processes, including the regulation of beginning of documented medical knowledge [1], immune response [3-7]. TRPM7, which possesses but the disclosure of its significance and com- an ion transport domain and an active kinase plexity is rather recent. It is now clear that domain and is responsible for cellular Mg homeo- inflammation is the automatic response of living stasis, phosphorylates phospholipase C␥2, crucial tissues to damage. Through a series of inter- in intracellular signaling after the activation of connected events involving blood vessels and B lymphocytes, and is implicated in T cell migra- leukocytes, it defends from damages and paves the tion [7, 8].
    [Show full text]
  • Schlenk Equilibrium in Toluene Solutions of Grignard Reagents
    SCHLENK EQUILIBRIUM IN TOLUENE SOLUTIONS OF GRIGNARD REAGENTS Ants Tuulmets*, Marvi Mikk and Dmitri Panov Institute of Organic Chemistry, University of Tartu, Tartu, EE2400 Estonia Abstract Grignard reagents were prepared from η-butyl chloride, η-butyl bromide and bromobenzene in toluene in the presence of small amounts of diethyl ether. The reagents disproportionate according to the Schlenk equilibrium with the formation of a precipitate rich in magnesium halide. The supernatant solution comprises higly soluble complexes of the stoichiometry xR2Mg.yMgX2.zEt20 (x>y). The extent of side-reactions during the formation of these Grignard reagents increases in the order nBuCI<nBuBr<PhBr. Introduction Organomagnesium compounds can be prepared not only in conventional ethers but also in hydrocarbon media or without any solvent at all [1-5]. For many purposes the replacement of ethers by hydrocarbons of higher boiling point is expedient. The process in hydrocarbons is preferable, since the reaction medium is cheap, nonhygroscopic, and fire hazards are low. The use of unsolvated organomagnesium halides is limited to primary alkyl and aryl compounds. Branched chain primary, secondary, and tertiary alkyl halides, vinyl, allyl, and benzyl halides do not react under these conditions or produce Wurtz-type coupling products [2,6]. In the presence of one molar equivalent of complexing agents, e.g. ethers and tertiary amines, several organomagnesium compounds have been obtained in hydrocarbon media [5,7,8], Furthermore, alkylmagnesium bromide and chloride reagents in toluene containing less than one equivalent of diethyl ether have also been prepared [9-12]. Because the Grignard reagents in donor solvents are complexed at least with two solvent molecules per atom of magnesium, the reagents obtained in the presence of smaller amounts of donors should be considered as partially solvated.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,284,263 B1 Place (45) Date of Patent: Sep
    USOO6284263B1 (12) United States Patent (10) Patent No.: US 6,284,263 B1 Place (45) Date of Patent: Sep. 4, 2001 (54) BUCCAL DRUG ADMINISTRATION IN THE 4,755,386 7/1988 Hsiao et al. TREATMENT OF FEMALE SEXUAL 4,764,378 8/1988 Keith et al.. DYSFUNCTION 4,877,774 10/1989 Pitha et al.. 5,135,752 8/1992 Snipes. 5,190,967 3/1993 Riley. (76) Inventor: Virgil A. Place, P.O. Box 44555-10 5,346,701 9/1994 Heiber et al. Ala Kahua, Kawaihae, HI (US) 96743 5,516,523 5/1996 Heiber et al. 5,543,154 8/1996 Rork et al. ........................ 424/133.1 (*) Notice: Subject to any disclaimer, the term of this 5,639,743 6/1997 Kaswan et al. patent is extended or adjusted under 35 6,180,682 1/2001 Place. U.S.C. 154(b) by 0 days. * cited by examiner (21) Appl. No.: 09/626,772 Primary Examiner Thurman K. Page ASSistant Examiner-Rachel M. Bennett (22) Filed: Jul. 27, 2000 (74) Attorney, Agent, or Firm-Dianne E. Reed; Reed & Related U.S. Application Data ASSciates (62) Division of application No. 09/237,713, filed on Jan. 26, (57) ABSTRACT 1999, now Pat. No. 6,117,446. A buccal dosage unit is provided for administering a com (51) Int. Cl. ............................. A61F 13/02; A61 K9/20; bination of Steroidal active agents to a female individual. A61K 47/30 The novel buccal drug delivery Systems may be used in (52) U.S. Cl. .......................... 424/435; 424/434; 424/464; female hormone replacement therapy, in female 514/772.3 contraception, to treat female Sexual dysfunction, and to treat or prevent a variety of conditions and disorders which (58) Field of Search ....................................
    [Show full text]
  • Standard Operating Procedures (Sop) for Working with Chloroform at Amherst College August 2019
    STANDARD OPERATING PROCEDURES (SOP) FOR WORKING WITH CHLOROFORM AT AMHERST COLLEGE AUGUST 2019 ____________________________________________________________________________________ General Information Chloroform, also known as trichloromethane, is a very volatile, sweet smelling, colorless liquid that is frequently used in the laboratory as a dilution solvent. In industry, it is commonly used in the production of the refrigerant Freon. Chloroform is an acutely toxic compound and is classified as a category 2 carcinogen. _____________________________________________________________________________________ Personal Protective Equipment When working with Chloroform, the following personal protective equipment (PPE) must be worn: Splash goggles Lab coat Long pants Close toed shoes Viton Gloves (Nitrile gloves may only be used if working with chloroform for less than 5 minutes and double gloving is employed; change gloves as often as needed). _____________________________________________________________________________________ Safety Devices Fume hood – always work with Chloroform in a fume hood to prevent exposure by inhalation. Identify the location of all the safety devices in the room before starting your procedure. Also, familiarize yourself with all the possible means of egress. Keep safety devices and means of egress clear at all times. _____________________________________________________________________________________ Specific Health Hazards Chloroform has an OSHA Permissible Exposure Limit (ceiling) of 50 ppm. This means that personnel
    [Show full text]
  • Ketamine Infusion Combined with Magnesium As a Therapy for Intractable Chronic Cluster Headache: Report of Two Cases
    ISSN 0017-8748 Headache doi: 10.1111/head.13135 VC 2017 American Headache Society Published by Wiley Periodicals, Inc. Brief Communications Ketamine Infusion Combined With Magnesium as a Therapy for Intractable Chronic Cluster Headache: Report of Two Cases Xavier Moisset, MD, PhD ; Pierre Clavelou, MD, PhD; Michel Lauxerois, MD; Radhouane Dallel, DDS, PhD; Pascale Picard, MD Background.—Chronic cluster headache (CH) is a rare, highly disabling primary headache condition. As NMDA receptors are possibly overactive in CH, NMDA receptor antagonists, such as ketamine, could be of interest in patients with intractable CH. Case reports.—Two Caucasian males, 28 and 45 years-old, with chronic intractable CH, received a single ketamine infusion (0.5 mg/kg over 2 h) combined with magnesium sulfate (3000 mg over 30 min) in an outpatient setting. This treat- ment led to a complete relief from symptoms (attack frequency and pain intensity) for one patient and partial relief (50%) for the other patient, for 6 weeks in both cases. Conclusion.—The NMDA receptor is a potential target for the treatment of chronic CH. Randomized, placebo- controlled studies are warranted to establish both safety and efficacy of such treatment. Key words: cluster headache, ketamine, NMDA Abbreviations: CH cluster headache, NMDA N-methyl-D-aspartate (Headache 2017;57:1261-1264) INTRODUCTION form of CH is rare, and its attacks recur over more Cluster headache (CH) is characterized by than 1 year without remission periods or with severe strictly unilateral headaches lasting 15- remission periods lasting less than 1 month.1 Some 180 min, accompanied by agitation and ipsilateral chronic CH patients become drug-resistant and autonomic phenomena, including rhinorrhea, lacri- continue to suffer almost daily attacks for long peri- mation, and conjunctival injection.1 The chronic ods.
    [Show full text]
  • The Effects of Combined Magnesium and Zinc Supplementation On
    Hamedifard et al. Lipids in Health and Disease (2020) 19:112 https://doi.org/10.1186/s12944-020-01298-4 RESEARCH Open Access The effects of combined magnesium and zinc supplementation on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease Zahra Hamedifard1, Alireza Farrokhian2, Željko Reiner3, Fereshteh Bahmani1, Zatollah Asemi1, Maryam Ghotbi1 and Mohsen Taghizadeh1* Abstract Background: The present research aimed to analyze the impacts of magnesium and zinc supplements on glycemic control, serum lipids, and biomarkers of oxidative stress and inflammation in patients suffering from coronary heart disease (CHD) and type 2 diabetes mellitus (T2DM). Methods: According to the research design, a randomized, double-blind, placebo-controlled trial has been implemented on 60 subjects suffering from CHD and T2DM. Therefore, participants have been randomly divided into 2 groups for taking placebo (n = 30) or 250 mg magnesium oxide plus 150 mg zinc sulfate (n = 30) for 12 weeks. Results: Magnesium and zinc significantly decreased fasting plasma glucose (FPG) (β − 9.44 mg/dL, 95% CI, − 18.30, − 0.57; P = 0.03) and insulin levels (β − 1.37 μIU/mL, 95% CI, − 2.57, − 0.18; P = 0.02). Moreover, HDL-cholesterol levels significantly enhanced (β 2.09 mg/dL, 95% CI, 0.05, 4.13; P = 0.04) in comparison to the placebo. There was an association between magnesium and zinc intake, and a significant decrease of C-reactive protein (CRP) (β − 0.85 mg/L, 95% CI, − 1.26, − 0.45; P < 0.001), a significant increase in total nitrite (β 5.13 μmol/L, 95% CI, 1.85, 8.41; P =0.003)and total antioxidant capacity (TAC) (β 43.44 mmol/L, 95% CI, 3.39, 83.50; P = 0.03) when compared with placebo.
    [Show full text]
  • Ketamine and Magnesium for Refractory Neuropathic Pain
    PAIN MEDICINE ABSTRACT Background: Ketamine is often used for the management of refractory chronic pain. There is, however, a paucity of trials exploring its analgesic effect several weeks after intravenous administration or in association with Ketamine and magnesium. The authors hypothesized that ketamine in neuropathic pain may provide pain relief and cognitive–emotional benefitversus placebo and that a Magnesium for Refractory combination with magnesium may have an additive effect for 5 weeks. Methods: A randomized, double-blind, crossover, placebo-controlled study Neuropathic Pain (NCT02467517) included 20 patients with neuropathic pain. Each ket- amine-naïve patient received one infusion every 35 days in a random order: Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/133/1/154/514260/20200700.0-00027.pdf by guest on 25 September 2021 A Randomized, Double-blind, ketamine (0.5 mg/kg)/placebo or ketamine (0.5 mg/kg)/magnesium sulfate Crossover Trial (3g) or placebo/placebo. The primary endpoint was the area under the curve of daily pain intensity for a Gisèle Pickering, M.D., Ph.D., D.Pharm., period of 35 days after infusion. Secondary endpoints included pain (at 7, 15, 21 Bruno Pereira, Ph.D., Véronique Morel, Ph.D., and 28 days) and health-related, emotional, sleep, and quality of life questionnaires. Alexandrine Corriger, Ph.D., Fatiha Giron, B.Sc., Results: Daily pain intensity was not significantly different between the three Fabienne Marcaillou, M.D., Assiya Bidar-Beauvallot, B.Sc., groups (n = 20) over 35 days (mean area under the curve = 185 ± 100, 196 Evelyne Chandeze, B.Sc., Céline Lambert, M.Sc., ± 92, and 187 ± 90 pain score-days for ketamine, ketamine/magnesium, and Lise Bernard, D.Pharm., Noémie Delage, M.D.
    [Show full text]
  • The Absorption and Retention of Magnesium, Zinc, and Copper by Low Birth Weight Infants Fed Pasteurized Human Breast Milk
    Pediat. Res. 11: 991-997 (1977) Absorption magnesium copper newborn low birth weight infants zinc The Absorption and Retention of Magnesium, Zinc, and Copper by Low Birth Weight Infants Fed pasteurized Human Breast Milk M. J. DAUNCEY, J. C. L. SHAW,'3" AND J. URMAN Depnrttnent of Poedintrics, University College Hospitnl, Londorz, and Medical Resenrcll Council Dicnn Nutrition Unit, Cilmbridge, England Summary about two-thirds of the magnesium and perhaps one-third of the zinc in the body are present in the bones. Because of the " Using serial metabolic balance techniques, the absorption and extensive remodeling of fetal bone after birth retention of magnesium, copper, and zinc have been measured much of the magnesium and zinc in bone, as well as the hepatic in six preterm infants (mean gestation 29 weeks), and two term copper, probably become available to meet the later needs of the , small for gestational age infants (<1.5 kg birth weight). The growing full term infant. amounts of the minerals retained were compared with the The infant born months prematurely, however, has much amounts retained by a fetus of equivalent ~e~~~~~~~~lage in smaller amounts of magnesium, copper, and zinc in his body, u tero . and must rely on the fetal intestine to absorb enough of these The preterm absorbed 5'3 * 3'5 mg/kg'day "lagne- substances for his needs. Cavell and Widdowson (4) showed that sium (43% of intake, range 1-74%) and retained 2.8 * 1.3 mg/ full term infants were in negative balance for copper and zinc in kg' (25% intake, range -I5 to +48%)' The mean postna- the newborn period, and the reports of Tkacenko (21) and of tal retention over the period, as a percentage of Widdowson et a/.
    [Show full text]
  • DE Medicaid MAC List Effective As of 1/5/2018
    OptumRx - DE Medicaid MAC List Effective as of 1/5/2018 Generic Label Name & Drug Strength Effective Date MAC Price OTHER IV THERAPY (OTIP) 10/25/2017 77.61750 PENICILLIN G POTASSIUM FOR INJ 5000000 UNIT 3/15/2017 8.00000 PENICILLIN G POTASSIUM FOR INJ 20000000 UNIT 3/15/2017 49.62000 PENICILLIN G SODIUM FOR INJ 5000000 UNIT 10/25/2017 53.57958 PENICILLIN V POTASSIUM TAB 250 MG 1/3/2018 0.05510 PENICILLIN V POTASSIUM TAB 500 MG 12/29/2017 0.10800 PENICILLIN V POTASSIUM FOR SOLN 125 MG/5ML 10/26/2017 0.02000 PENICILLIN V POTASSIUM FOR SOLN 250 MG/5ML 12/22/2017 0.02000 AMOXICILLIN (TRIHYDRATE) CAP 250 MG 12/22/2017 0.03930 AMOXICILLIN (TRIHYDRATE) CAP 500 MG 11/1/2017 0.05000 AMOXICILLIN (TRIHYDRATE) TAB 500 MG 12/28/2017 0.20630 AMOXICILLIN (TRIHYDRATE) TAB 875 MG 10/31/2017 0.08000 AMOXICILLIN (TRIHYDRATE) CHEW TAB 125 MG 10/26/2017 0.12000 AMOXICILLIN (TRIHYDRATE) CHEW TAB 250 MG 10/26/2017 0.24000 AMOXICILLIN (TRIHYDRATE) FOR SUSP 125 MG/5ML 10/28/2017 0.00667 AMOXICILLIN (TRIHYDRATE) FOR SUSP 200 MG/5ML 12/20/2017 0.01240 AMOXICILLIN (TRIHYDRATE) FOR SUSP 250 MG/5ML 12/18/2017 0.00980 AMOXICILLIN (TRIHYDRATE) FOR SUSP 400 MG/5ML 12/28/2017 0.01310 AMPICILLIN CAP 250 MG 9/26/2017 0.07154 AMPICILLIN CAP 500 MG 11/6/2017 0.24000 AMPICILLIN FOR SUSP 125 MG/5ML 3/17/2017 0.02825 AMPICILLIN FOR SUSP 250 MG/5ML 9/15/2017 0.00491 AMPICILLIN SODIUM FOR INJ 250 MG 3/15/2017 1.38900 AMPICILLIN SODIUM FOR INJ 500 MG 7/16/2016 1.02520 AMPICILLIN SODIUM FOR INJ 1 GM 12/20/2017 2.00370 AMPICILLIN SODIUM FOR IV SOLN 1 GM 7/16/2016 15.76300 AMPICILLIN
    [Show full text]
  • Thermal and Combined Thermal and Radiolytic Reactions Involving
    PNL-10490 Thermal and Combined Thermal and Radiolytic Reactions Involving Nitrous Oxide, Hydrogen, and Nitrogen in the Gas Phase; Comparison of Gas Generation Rates in Supernate and Solid Fractions of Tank 241-SY-101 Simulated Waste S. A. Bryan L R. Pederson March 1995 Prepared for the U.S. Department of Energy under Contract DE-AC06-76RL0 1830 Pacific Northwest Laboratory Richland, Washington 99352 DISTRIBUTION OF THIC DOCUMENT IS UNLIMITED IT DISCLAIMER Portions of this document may be illegible in electronic image products. Images are produced from the best available original document. Executive Summary This report summarizes progress made in evaluating mechanisms by which flammable gases are generated in Hanford double-shell tank wastes, based on the results of laboratory tests using simulated waste mixtures. Work described in this report was conducted at Pacific Northwest Laboratory (PNL)(a) for the Flammable Gas Safety Project, the purpose of which is to develop information needed to support Westinghouse Hanford Company (WHC) in their efforts to ensure the safe interim storage of wastes at the Hanford Site. This work is related to gas generation studies being performed at Georgia Institute of Technology (GIT), under subcontract to PNL, using simulated wastes, and to studies being performed at WHC using actual wastes. Described in this report are 1) the results of tests to evaluate the rates of thermal and combined thermal and radiolytic reactions involving flammable gases, and 2) the results of experiments intended to compare gas generation rates in a homogeneous liquid with those in a heterogeneous slurry. Flam• mable gases generated by the radiolysis of water and by the thermal and radiolytic decomposition of organic waste constituents may themselves participate in further reactions.
    [Show full text]